{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:22:03Z","timestamp":1708042923259},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"No funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/14656566.2024.2303425","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:40:51Z","timestamp":1704706851000},"page":"37-44","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical guidance for choosing the right pharmacotherapy for migraine attacks"],"prefix":"10.1080","volume":"25","author":[{"given":"Izabela","family":"Domitrz","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Bielanski Hospital, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415620251"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0846-2"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010634"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01097.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12835"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2021.0007"},{"key":"e_1_3_4_14_1","first-page":"AMS-16153-2023","article-title":"The Polish experts\u2019 consensus statement: 2023 update on new therapies for migraine","volume":"1","author":"Domitrz I","year":"2024","unstructured":"Domitrz I, Kozubski W, Boczarska-Jedynak M, et al. The Polish experts\u2019 consensus statement: 2023 update on new therapies for migraine. Arch Med Sci. 2024;1(vol20):AMS-16153-2023\u201302.","journal-title":"Arch Med Sci"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00045-9"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00948.x"},{"key":"e_1_3_4_18_1","volume-title":"Program and abstracts of the 55th Annual Scientific Meeting of the American Academy of Neurology, March 29-April 5","author":"Goldstein J","year":"2003","unstructured":"Goldstein J, Silberstein SD, Elkind AH, et al. A placebo-controlled comparison of the combination of acetaminophen, aspirin, and caffeine with sumatriptan succinate in the early treatment of migraine: results from the asset trial. Program and abstracts of the 55th Annual Scientific Meeting of the American Academy of Neurology, March 29-April 5; 2003; Honolulu, Hawaii. Abstract S22.005."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00783.x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000150904.28131.DD"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1506531.x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1993.1302117.x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13663"},{"key":"e_1_3_4_24_1","unstructured":"Drug Approval Package: Elyxyb. [cited 2021 Mar 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212157Orig1s000TOC.cfm"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01594.x"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06711-3"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00914.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-5101.2003.00730.x"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00895.x"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01546.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420915167"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00082.x"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12052"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110312.36809.7F"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00694.x"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410375512"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410370873"},{"issue":"24","key":"e_1_3_4_39_1","first-page":"e2222","article-title":"Lasmiditan is an effective acute treatment for migraine. A phase 3 randomized study","volume":"91","author":"on behalf of the COL MIG-301 Study Group","year":"2018","unstructured":"on behalf of the COL MIG-301 Study Group, Kuca B, Silberstein SD, et al. Lasmiditan is an effective acute treatment for migraine. A phase 3 randomized study. Neurology. 2018;91(24):e2222\u2013e2232.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_4_40_1","first-page":"209","article-title":"Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine","volume":"11","author":"Farkkila M","year":"2010","unstructured":"Farkkila M, Diener H-C, Lainez JM, et al. Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain. 2010;11(Supl 1):209.","journal-title":"J Headache Pain"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420920006"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1694"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1701"},{"key":"e_1_3_4_45_1","first-page":"9.12","volume-title":"Presented at Presented at the American Academy of Neurology Annual Meeting","author":"Tourias K","year":"2023","unstructured":"Tourias K, Pavitt S Safety and efficacy of oral calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine in the pediatric population. Presented at Presented at the American Academy of Neurology Annual Meeting; 2023 Apr 22-27; Boston, USA. p. 9.12\u2013010"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1694"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261065"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00715-7"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13766"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13010004"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01240"},{"key":"e_1_3_4_54_1","volume-title":"Presented at the American Academy of Neurology Annual Meeting","author":"Goadsby PJ","year":"2023","unstructured":"Goadsby PJ, Ailani J, Dodick DW, et al. Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): results from the PRODROME trial. Presented at the American Academy of Neurology Annual Meeting; 2023 Apr 22-27; Boston, USA. p.S47.002"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_4_57_1","unstructured":"Drug approval package: nurtec ODT. [cited 2021 Mar 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212728Orig1s000TOC.cfm."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000204155"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00125.x"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00364.x"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00867.x"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13434"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12375"},{"key":"e_1_3_4_64_1","first-page":"271","article-title":"Efficacy of intramuscular droperidol for migraine treatment: a dose-response study","volume":"21","author":"Silberstein S","year":"2001","unstructured":"Silberstein S, Young WB, Mendizabal JE, et al. Efficacy of intramuscular droperidol for migraine treatment: a dose-response study. Cephalalgia. 2001;21:271\u2013272.","journal-title":"Cephalalgia"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2003.195"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000150904.28131.DD"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207648"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0250"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2303425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T08:02:10Z","timestamp":1707984130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2303425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/14656566.2024.2303425"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2303425","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}